Journal
CELLS
Volume 8, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cells8050470
Keywords
drug screening; cancer; cell lines; organoid; spheroid; heterogeneity; precision medicine
Categories
Funding
- P-DIRECT, P-CREATE, Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) [JP18am0101084]
- Research on Development of New Drugs, from Japan Agency for Medical Research and Development, AMED, Research Grant of the Princess Takamatsu Cancer Research Fund
Ask authors/readers for more resources
Drug screeningi.e., testing the effects of a number of drugs in multiple cell linesis used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available